Hapvida - Q1 2026 Earnings Analysis

Performance Highlights

Hapvida reported Q1 2026 net revenue of R$7,892 million, up 5.2% year-over-year but essentially flat versus Q4 2025, beating the prior-year comparable on average ticket growth of 7.3% that more than offset a net health beneficiary decline of 114,100 members over the same period. Adjusted EBITDA reached R$803 million (10.2% margin), a 300 bps sequential improvement excluding one-off events, though still 321 bps below the Q1 2025 margin of 13.4%, underscoring the distance remaining in the profitability recovery.

The single most important driver in the quarter was the 328 bps sequential compression in Cash MLR from 75.5% to 72.2%, reflecting normalised claims carryover from a seasonally lighter December and typical Carnival-period patterns in January and February, partially offset by above-trend March volumes as elective demand rebounded. Supporting this, free cash flow conversion reached 81.1% of Adjusted EBITDA at R$443 million, net debt edged down R$18 million to R$5,165 million, and leverage held at a manageable 1.38x LTM EBITDA against a contractual covenant threshold.

Management Outlook and Forward Catalysts

Management framed Q1 2026 explicitly as a "clean quarter" and the starting point of a structured turnaround, centred on five pillars: customer experience, commercial repositioning, own-network optimisation, technology and AI federalisation, and financial discipline. New CEO Luccas Adib highlighted responsible geographic decentralisation, a simplified product and pricing architecture in São Paulo, and a forthcoming NotreDame Saúde premium brand launch as near-term commercial catalysts, signalling a business in active reorganisation rather than steady-state operation.

The central investor debate heading into Q2 2026 is whether the sequential MLR improvement is structurally durable or partly seasonal, given March utilisation already rebounded above historical norms and Cash G&A jumped to 8.0% of net revenue on rising contingency provisions. Bulls will focus on retail net adds recovering in the São Paulo Metropolitan Region and dental beneficiary growth of 60,300 in the quarter; bears will watch whether beneficiary losses in the corporate and individual channels stabilise, and whether leverage creeping toward 1.38x constrains the capital needed to fund the turnaround investments in IT, network infrastructure, and regional expansion.